View ValuationTechno Drugs 将来の成長Future 基準チェック /06現在、 Techno Drugsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.お知らせ • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladeshお知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025お知らせ • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.お知らせ • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Techno Drugs は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DSE:TECHNODRUG - アナリストの将来予測と過去の財務データ ( )BDT Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20253,150206-145311N/A9/30/20253,233216-570180N/A6/30/20253,376232-481189N/A3/31/20253,127223-613171N/A12/31/20242,993219-428337N/A9/30/20243,17625645315N/A6/30/20243,61328184428N/A6/30/20232,733196-421210N/A6/30/20225,029480-2593N/Aアナリストによる今後の成長予測収入対貯蓄率: TECHNODRUGの予測収益成長が 貯蓄率 ( 4.2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: TECHNODRUGの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: TECHNODRUGの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: TECHNODRUGの収益がBD市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: TECHNODRUGの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: TECHNODRUGの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 21:04終値2026/05/21 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Techno Drugs Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026
お知らせ • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
お知らせ • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
お知らせ • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh
お知らせ • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
お知らせ • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
お知らせ • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
お知らせ • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
お知らせ • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.
お知らせ • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024
New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.
Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.